Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.

Autor: Lee MD; Department of Radiology, NYU Grossman School of Medicine, New York, NY, USA. matthew.lee4@nyulangone.org., Patel SH; Department of Radiology, University of Virginia School of Medicine, Charlottesville, VA, USA., Mohan S; Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Akbari H; Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA.; Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Bakas S; Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA.; Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Nasrallah MP; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; Glioblastoma Multiforme Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Calabrese E; Department of Radiology, Division of Neuroradiology, Duke University, Durham, NC, USA., Rudie J; Department of Radiology, University of California San Diego, San Diego, CA, USA., Villanueva-Meyer J; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA., LaMontagne P; Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA., Marcus DS; Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA., Colen RR; Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.; Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Balana C; Medical Oncology Department, Catalan Institute of Oncology (ICO), Barcelona, Spain., Choi YS; Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, South Korea., Badve C; Department of Radiology, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA., Barnholtz-Sloan JS; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD, USA.; Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA., Sloan AE; Department of Neurosurgery, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA.; Seidman Cancer Center and Case Comprehensive Cancer Center, Cleveland, OH, USA., Booth TC; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.; Department of Neuroradiology, King's College Hospital NHS Foundation Trust, Ruskin WingLondon, UK., Palmer JD; Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA., Dicker AP; Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Flanders AE; Department of Radiology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Shi W; Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Griffith B; Department of Radiology, Henry Ford Health, Detroit, MI, USA., Poisson LM; Department of Public Health Sciences, Center for Bioinformatics, Henry Ford Health, Detroit, MI, USA., Chakravarti A; Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA., Mahajan A; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK., Chang S; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA., Orringer D; Department of Neurosurgery, NYU Grossman School of Medicine, New York, NY, USA.; Department of Pathology, NYU Grossman School of Medicine, New York, NY, USA., Davatzikos C; Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA.; Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Jain R; Department of Radiology, NYU Grossman School of Medicine, New York, NY, USA.; Department of Neurosurgery, NYU Grossman School of Medicine, New York, NY, USA.
Jazyk: angličtina
Zdroj: Neuroradiology [Neuroradiology] 2023 Sep; Vol. 65 (9), pp. 1343-1352. Date of Electronic Publication: 2023 Jul 19.
DOI: 10.1007/s00234-023-03196-9
Abstrakt: Purpose: While the T2-FLAIR mismatch sign is highly specific for isocitrate dehydrogenase (IDH)-mutant, 1p/19q-noncodeleted astrocytomas among lower-grade gliomas, its utility in WHO grade 4 gliomas is not well-studied. We derived the partial T2-FLAIR mismatch sign as an imaging biomarker for IDH mutation in WHO grade 4 gliomas.
Methods: Preoperative MRI scans of adult WHO grade 4 glioma patients (n = 2165) from the multi-institutional ReSPOND (Radiomics Signatures for PrecisiON Diagnostics) consortium were analyzed. Diagnostic performance of the partial T2-FLAIR mismatch sign was evaluated. Subset analyses were performed to assess associations of imaging markers with overall survival (OS).
Results: One hundred twenty-one (5.6%) of 2165 grade 4 gliomas were IDH-mutant. Partial T2-FLAIR mismatch was present in 40 (1.8%) cases, 32 of which were IDH-mutant, yielding 26.4% sensitivity, 99.6% specificity, 80.0% positive predictive value, and 95.8% negative predictive value. Multivariate logistic regression demonstrated IDH mutation was significantly associated with partial T2-FLAIR mismatch (odds ratio [OR] 5.715, 95% CI [1.896, 17.221], p = 0.002), younger age (OR 0.911 [0.895, 0.927], p < 0.001), tumor centered in frontal lobe (OR 3.842, [2.361, 6.251], p < 0.001), absence of multicentricity (OR 0.173, [0.049, 0.612], p = 0.007), and presence of cystic (OR 6.596, [3.023, 14.391], p < 0.001) or non-enhancing solid components (OR 6.069, [3.371, 10.928], p < 0.001). Multivariate Cox analysis demonstrated cystic components (p = 0.024) and non-enhancing solid components (p = 0.003) were associated with longer OS, while older age (p < 0.001), frontal lobe center (p = 0.008), multifocality (p < 0.001), and multicentricity (p < 0.001) were associated with shorter OS.
Conclusion: Partial T2-FLAIR mismatch sign is highly specific for IDH mutation in WHO grade 4 gliomas.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: